Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Endurance Bio Inc. pioneers orally bioavailable small molecules (T-168, Phase 2; T-621, preclinical) that upregulate PGC-1α to enhance mitochondrial health. Our compounds also activate TFEB/TRPML1, improving lysosomal function and cellular homeostasis. Targeting diseases linked to mitochondrial and lysosomal dysfunction, we aim to transform treatment paradigms with innovative therapies.

List your booth number for exhibitions, ask us